Drug - Xyrem (sodium oxybate) [Jazz Pharmaceuticals]
October 2010
Treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Xyrem will NOT be approved for fibromyalgia. Xyrem was reviewed by the FDA for fibromyalgia, and this indication was rejected in October of 2010.
The active ingredient of Xyrem is a form of gamma-hydroxybutyrate (GHB), which rapidly produces deep sedation. GHB is a chemical that has been abused and misused. Abuse and misuse of Xyrem can cause serious medical problems, which may include seizures, loss of consciousness, coma and death. Abuse of Xyrem can lead to dependence, which may include craving for the medicine and severe withdrawal symptoms.
Xyrem is available only through a central pharmacy that provides educational material to the prescriber and the patient explaining the risks and proper use of sodium oxybate, and the required prescription form. Once it is documented that the patient has read and/or understood the materials, the drug will be shipped to the patient. The Xyrem Success Program also recommends patient follow-up every 3 months. Physicians are expected to report all serious adverse events to the manufacturer.
MHCP Provider Call Center 651-431-2700 or 800-366-5411
